Clinical Trial Update: Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity [Phase 4]

View source ↗

Summary

Phase 4 trial investigating intratympanic N-acetylcysteine to protect against cisplatin-induced ototoxicity was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ototoxic Hearing Loss
• Tinnitus

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Centre Hospitalier Universitaire Saint Pierre | Conditions: Ototoxic Hearing Loss, Ototoxic Hearing Loss, Bilateral | Phase 4 | Status: TERMINATED